Cao Louie, Kim Seongkyu, Klapper Ellen, Kobashigawa Jon A, Kittleson Michelle M
Department of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
J Clin Med. 2023 Feb 8;12(4):1337. doi: 10.3390/jcm12041337.
There are subtypes within blood type A, termed non-A1, that have reduced expression of A antigen on cell surfaces. This can result in the development of anti-A1 antibodies. There is limited information regarding the impact of this in heart transplant (HTx) recipients. We conducted a single-center cohort study of 142 Type A HTx recipients in which we compared outcomes of a match group (an A1/O heart into an A1 recipient or a non-A1/O heart into a non-A1 recipient) with a mismatch group (an A1 heart into a non-A1 recipient or a non-A1 heart into an A1 recipient). At one year post-transplant, there were no differences between the groups in survival, freedom from non-fatal major adverse cardiovascular events, freedom from any treated rejection, or freedom from cardiac allograft vasculopathy. There was an increased hospital length of stay in the mismatch group (13.5 vs. 17.1 days, = 0.04). Our study showed that A1 mismatch was not associated with worse outcomes at one year post-HTx.
A型血存在一些亚型,称为非A1型,其细胞表面A抗原的表达减少。这可能导致抗A1抗体的产生。关于这在心脏移植(HTx)受者中的影响,相关信息有限。我们对142例A型HTx受者进行了一项单中心队列研究,在此研究中,我们将匹配组(A1/O心脏移植给A1受者或非A1/O心脏移植给非A1受者)与不匹配组(A1心脏移植给非A1受者或非A1心脏移植给A1受者)的结果进行了比较。移植后一年,两组在生存率、无非致命性主要不良心血管事件、无任何经治疗的排斥反应或无心脏移植血管病变方面没有差异。不匹配组的住院时间有所延长(13.5天对17.1天,P = 0.04)。我们的研究表明,A1不匹配与HTx后一年的不良结果无关。